AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Silo Pharma, Inc. Director's Dealing 2022

Dec 15, 2022

35304_dirs_2022-12-15_45a60ede-8bd5-4968-a912-f935594fc2b4.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Silo Pharma, Inc. (SILO)
CIK: 0001514183
Period of Report: 2022-12-13

Reporting Person: Weisblum Eric (Director, CEO and President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-12-13	Common Stock	P	487	$3.0676	Acquired	154261	Direct
2022-12-14	Common Stock	P	263	$3.1699	Acquired	154524	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.992 to $3.20. The reporting person undertakes to provide Silo Pharma, Inc., any security holder of Silo Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.